Effects of melatonin in polycystic ovary syndrome: is there Hippo pathway crosstalk?

Lijun Wang, Yuanyuan Jin, Yuanyuan Zhi, Zhenzhen Li, Meili Wang, Boda Wang, Xinbo WangJournal of Ovarian Research 2025 · DOI

TL;DR

This review explores the therapeutic potential of melatonin (MT) in treating Polycystic Ovary Syndrome (PCOS) by investigating its "crosstalk" with the Hippo signaling pathway. The authors suggest that melatonin does more than just regulate sleep; it may actively recalibrate ovarian function by modulating the Hippo pathway to reduce ovarian stiffness, lower androgen levels, and improve insulin sensitivity.

What Problem Does This Paper Address?

Polycystic Ovary Syndrome (PCOS) affects approximately 20% of women of reproductive age, leading to infertility, metabolic dysfunction, and insulin resistance. Current treatments like metformin or hormonal contraceptives often come with significant side effects or provide incomplete relief.

While melatonin has emerged as a promising alternative therapy due to its antioxidant and endocrine-regulating properties, its exact molecular mechanism in the context of PCOS has remained elusive. This paper addresses the gap by synthesizing recent research to propose a specific molecular link: the interaction between melatonin-activated G-protein coupled receptors (GPCRs) and the Hippo pathway—a master regulator of organ size and cell proliferation that is often dysregulated in PCOS.

Methods

As a comprehensive review, this paper consolidates and analyzes data from three primary levels of research over the last decade:

  • Molecular/In Vitro Studies: Examining the effects of melatonin on human and rodent granulosa cells (GCs).
  • Animal Models: Analyzing results from rodent models where PCOS-like phenotypes were induced via androgens (DHEA/Testosterone), aromatase inhibitors (Letrozole), or continuous light exposure.
  • Human Randomized Controlled Trials (RCTs): Evaluating clinical outcomes in women with PCOS receiving melatonin supplements (ranging from 2mg to 10mg daily).

The authors specifically focus on the signaling cascade involving MT1/MT2 receptors, cAMP levels, and the phosphorylation of YAP (Yes-associated protein), a key effector of the Hippo pathway.

Datasets

The review synthesizes findings from:

  • 5 Molecular Studies: Focusing on signaling pathways like PI3K/Akt and SIRT1.
  • 8 Animal Studies: Primarily using Sprague-Dawley rats and C57BL/6 mice.
  • 7 Human Clinical Trials: Including studies on IVF/ICSI outcomes, sleep quality (PSQI), and metabolic markers (HOMA-IR).

Key Insights and Ideas

  • The "Stiff Ovary" Hypothesis: In PCOS, the ovarian cortex becomes abnormally rigid due to increased collagen and actin polymerization. This physical stiffness "turns off" the Hippo pathway, allowing the protein YAP to enter the nucleus. Once in the nucleus, YAP triggers the growth of multiple small follicles that never reach ovulation—the hallmark of PCOS.
  • Melatonin as a Hippo Activator: The paper proposes that melatonin binds to MT receptors, triggering a G-protein cascade (Gαs) that increases intracellular cAMP. This activates the Hippo kinase chain (LATS1/2), which phosphorylates YAP, keeping it trapped in the cytoplasm and preventing it from driving PCOS pathogenesis.
  • Metabolic-Hormonal Synergy: Melatonin appears to act on multiple fronts simultaneously. It improves insulin signaling (via IRS-1 and GLUT4) and reduces oxidative stress in the follicular fluid, which creates a more favorable environment for oocyte maturation.
  • Circadian Disruption: Women with PCOS often show diminished nocturnal melatonin variation. Restoring this rhythm through supplementation may help normalize the hypothalamus-hypophysis-ovary (HHO) axis.

Key Results

  • Clinical Improvements: In human RCTs, melatonin supplementation (typically 3–10 mg/day) significantly reduced serum androgens (testosterone) and Anti-Müllerian Hormone (AMH) levels while restoring regular menstrual cycles.
  • IVF Success: One double-blind RCT of 198 patients found that melatonin significantly improved follicle quality, endometrial thickness, and chemical pregnancy rates.
  • Metabolic Markers: Studies showed a decrease in C-reactive protein (CRP) and malondialdehyde (MDA), alongside improved insulin sensitivity (QUICKI index) and sleep quality.
  • Morphological Restoration: In animal models, melatonin treatment led to a decrease in cystic follicles and an increase in the presence of the corpus luteum, indicating successful ovulation.

Limitations and Future Work

  • Dosage Standardization: There is currently no consensus on the optimal dose or duration for melatonin therapy in PCOS, with studies varying widely from 2mg to 10mg.
  • Species Translation: Most mechanistic data comes from rodents, which are monoovulatory and have different circadian triggers than humans. The authors note that melatonin can increase insulin secretion in humans but has been shown to decrease it in some rodent models.
  • Direct Evidence Needed: While the theoretical "crosstalk" between melatonin and the Hippo pathway is supported by adjacent fields (like cancer research), direct experimental evidence specifically in PCOS-afflicted ovaries is still limited.
  • Long-term Safety: More research is needed to determine the long-term effects of high-dose melatonin on the reproductive axis in adolescent girls and women of reproductive age.

Summary updated

Abstract

Not applicable.
BibTeX
@article{wang2025effects,
  author = {Lijun Wang and Yuanyuan Jin and Yuanyuan Zhi and Zhenzhen Li and Meili Wang and Boda Wang and Xinbo Wang},
  title = {{Effects of melatonin in polycystic ovary syndrome: is there Hippo pathway crosstalk?}},
  journal = {Journal of Ovarian Research},
  year = {2025},
  doi = {10.1186/s13048-025-01642-1},
}
Figure